Quick Answer
Stoke Therapeutics, Inc. reported Research And Development Expense of $137.92 million for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +54.7% in Research And Development Expense from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $1.89 million | Q3 2018: $2.23 million | Q1 2019: $4.13 million | Q2 2019: $6.02 million | Q3 2019: $6.52 million | Q1 2020: $7.22 million | Q2 2020: $7.97 million | Q3 2020: $8.11 million | Q1 2021: $9.91 million | Q2 2021: $14.10 million | Q3 2021: $14.36 million | Q1 2022: $18.31 million | Q2 2022: $18.36 million | Q3 2022: $20.11 million | Q1 2023: $19.63 million | Q2 2023: $20.55 million | Q3 2023: $20.27 million | Q1 2024: $22.37 million | Q2 2024: $21.14 million | Q3 2024: $22.21 million | Q1 2025: $32.68 million | Q2 2025: $25.86 million | Q3 2025: $37.70 million.
- Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Research And Development Expense has grown by 1,547.6%.
- Historical annual values: Fiscal year 2025: $137.92 million | Fiscal year 2024: $89.13 million | Fiscal year 2023: $82.23 million | Fiscal year 2022: $77.84 million | Fiscal year 2021: $54.17 million | Fiscal year 2020: $32.20 million | Fiscal year 2019: $23.76 million | Fiscal year 2018: $8.37 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: